Beta Bionics (BBNX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.38

Estimate

-$0.51

Surprise

+26.6%

Revenue (period 2026-09-30)

$35.5M

Score today

5.9/10

Revenue source: xbrl.

Beta Bionics (BBNX) reported a narrower loss than forecast — adjusted EPS of -$0.38 against the -$0.51 estimate (a 26.6% beat on a still-unprofitable quarter).

• 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga, 2026-10-28
• TD Cowen Maintains Hold on Beta Bionics, Raises Price Target to $21 — benzinga, 2026-10-28
• Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24 — benzinga, 2026-10-28

TrendMatrix currently rates BBNX Sell at 5.9/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +26.6% surprise compares with a +33.0% four-quarter average. Next scheduled report: 2027-02-16.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$18.41

Price target

$21.84

Stop

$17.12

Upside to target

+18.6%

Reward-to-risk

1.2:1

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$962.9M

P/E (fwd)

-8.4

52-week range

$8.80–$32.71

Off 52-week high

43.7%

RSI (14)

53

Volume vs avg

0.13×

Score today

5.9/10